Oramed Pharmaceuticals Issues Letter to Shareholders

Key Highlights – expected completion in YR 2025:

NEW YORK, March 4, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a letter to its shareholders from its President and Chief Executive Officer Nadav Kidron.

Read more at prnewswire.com